US Stock MarketDetailed Quotes

CANF Can-Fite BioPharma

Watchlist

1.4800
+0.0012+0.08%

Close Mar 31 16:00 ET

9.02MMarket Cap-0.57P/E (TTM)

Can-Fite BioPharma Stock Forum

Trytosaveabit

Mar 28 21:13

Maybe some good stuff will come outadis?

$Can-Fite BioPharma (CANF.US)$ $bioAffinity Technologies (BIAF.US)$ BioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Accesswire· 10 mins ago
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money show, a spo...

Teddy123

Mar 24 21:08

Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol

$Can-Fite BioPharma (CANF.US)$
Major Breakthrough: New Oral Psoriasis Drug Enters Final Testing Phase with Dual Regulatory Backing

Jaguar8

Mar 24 21:00

NEWS

$Can-Fite BioPharma (CANF.US)$
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Monday, 24th March at 9:00 am
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs
Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflam...

stderr

Mar 21 04:18

$Can-Fite BioPharma (CANF.US)$ How low?

151172736

Mar 20 21:54

$Can-Fite BioPharma (CANF.US)$ if you short this that means you hate dogs and people with cancer

Trytosaveabit

Mar 20 21:54

Update

$Can-Fite BioPharma (CANF.US)$ Can-Fite's upfront and royalties on sales upon regulatory approval of Piclidenoson for veterinary use, is projected to be $325 million in the aggregate over the next decade assuming a 2029 launch
Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it...

Teddy123

Mar 20 21:48

Biotech Analysis

$Can-Fite BioPharma (CANF.US)$
Can-Fite's veterinary partnership with Vetbiolix represents a strategic expansion into the $3.8 billion companion animal arthritis market, with Piclidenoson now advancing to an advanced clinical study following successful initial results. The move leverages their existing A3 Adenosine Receptor technology platform into veterinary medicine, where development timelines and approval processes are typically accelerated compared to human therapeutics.
The...

Teddy123

Mar 20 21:46

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

$Can-Fite BioPharma (CANF.US)$
Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity

Teddy123

Mar 19 21:05

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

$Can-Fite BioPharma (CANF.US)$
Breakthrough: Can-Fite's Piclidenoson Could Be First Drug for Fatal Genetic Disease

Trytosaveabit

Mar 19 21:04

update

$Can-Fite BioPharma (CANF.US)$ Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
3 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological ...